Walker, Kenneth W.,Holder, Jerry Ryan,Lloyd, David J.,Lu, Shu-Chen,Veniant-Ellison, Murielle M.,Stanislaus, Shanaka
申请号：
AU2018288852
公开号：
AU2018288852A1
申请日:
2018.06.20
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
Method of treating metabolic diseases and disorders using a composition comprising a GLP-l/GIPR antigen binding protein fusion protein are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises the C-terminus of a GLP-1 analog fused to the N-terminus of the light chain variable or heavy chain variable region of an antibody or functional fragment thereof that binds GIPR, optionally with a linker in between.
